Will the Invesco Pharma ETF or iShares Global Healthcare Fund Be the Better Health Care Fund in 2026?

This article from The Motley Fool compares the Invesco Pharmaceuticals ETF (PJP) and the iShares Global Healthcare ETF (IXJ) as investment options for 2026. PJP offers concentrated U.S. pharma exposure with 29 holdings, a 0.57% expense ratio, and a 0.90% dividend yield, while IXJ provides diversified global healthcare exposure with 110 holdings, a 0.40% expense ratio, and a 1.50% yield. Despite IXJ's lower cost and higher yield, PJP outperforms in most time frames (year-to-date, 3-year, and 5-year returns) with smaller maximum drawdown. Both funds have similar top-10 concentration (47-48%), but PJP has a higher allocation to small caps (43%) versus IXJ's large-cap focus (70%). The analysis concludes that PJP is the better buy for investors seeking healthcare exposure.